Skip to main content

A genetically engineered, stem-cell-derived cellular vaccine.

Publication ,  Journal Article
Cooper, A; Sidaway, A; Chandrashekar, A; Latta, E; Chakraborty, K; Yu, J; McMahan, K; Giffin, V; Manickam, C; Kroll, K; Mosher, M; Reeves, RK ...
Published in: Cell Rep Med
December 20, 2022

Despite rapid clinical translation of COVID-19 vaccines in response to the global pandemic, an opportunity remains for vaccine technology innovation to address current limitations and meet challenges of inevitable future pandemics. We describe a universal vaccine cell (UVC) genetically engineered to mimic natural physiological immunity induced upon viral infection of host cells. Cells engineered to express the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike as a representative viral antigen induce robust neutralizing antibodies in immunized non-human primates. Similar titers generated in this established non-human primate (NHP) model have translated into protective human neutralizing antibody levels in SARS-CoV-2-vaccinated individuals. Animals vaccinated with ancestral spike antigens and subsequently challenged with SARS-CoV-2 Delta variant in a heterologous challenge have an approximately 3 log decrease in viral subgenomic RNA in the lungs. This cellular vaccine is designed as a scalable cell line with a modular poly-antigenic payload, allowing for rapid, large-scale clinical manufacturing and use in an evolving viral variant environment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cell Rep Med

DOI

EISSN

2666-3791

Publication Date

December 20, 2022

Volume

3

Issue

12

Start / End Page

100843

Location

United States

Related Subject Headings

  • Viral Vaccines
  • SARS-CoV-2
  • Humans
  • COVID-19 Vaccines
  • COVID-19
  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Animals
  • 32 Biomedical and clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cooper, A., Sidaway, A., Chandrashekar, A., Latta, E., Chakraborty, K., Yu, J., … Barouch, D. H. (2022). A genetically engineered, stem-cell-derived cellular vaccine. Cell Rep Med, 3(12), 100843. https://doi.org/10.1016/j.xcrm.2022.100843
Cooper, Amanda, Adam Sidaway, Abishek Chandrashekar, Elizabeth Latta, Krishnendu Chakraborty, Jingyou Yu, Katherine McMahan, et al. “A genetically engineered, stem-cell-derived cellular vaccine.Cell Rep Med 3, no. 12 (December 20, 2022): 100843. https://doi.org/10.1016/j.xcrm.2022.100843.
Cooper A, Sidaway A, Chandrashekar A, Latta E, Chakraborty K, Yu J, et al. A genetically engineered, stem-cell-derived cellular vaccine. Cell Rep Med. 2022 Dec 20;3(12):100843.
Cooper, Amanda, et al. “A genetically engineered, stem-cell-derived cellular vaccine.Cell Rep Med, vol. 3, no. 12, Dec. 2022, p. 100843. Pubmed, doi:10.1016/j.xcrm.2022.100843.
Cooper A, Sidaway A, Chandrashekar A, Latta E, Chakraborty K, Yu J, McMahan K, Giffin V, Manickam C, Kroll K, Mosher M, Reeves RK, Gam R, Arthofer E, Choudhry M, Henley T, Barouch DH. A genetically engineered, stem-cell-derived cellular vaccine. Cell Rep Med. 2022 Dec 20;3(12):100843.

Published In

Cell Rep Med

DOI

EISSN

2666-3791

Publication Date

December 20, 2022

Volume

3

Issue

12

Start / End Page

100843

Location

United States

Related Subject Headings

  • Viral Vaccines
  • SARS-CoV-2
  • Humans
  • COVID-19 Vaccines
  • COVID-19
  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Animals
  • 32 Biomedical and clinical sciences